Context

Around the world, HTA agencies, government health departments and units are working hard to respond to the decision-making needs of their local areas during a state of global crisis.

Initially, the community was in immediate response mode, under pressure to identify, review, synthesize and formulate recommendations on a wave of queries related to the prevention, diagnosis, and/or treatment of coronaviruses and well beyond. We have had to deal with the obstacle of questionably tight response time frames, adding pressure to making informed decisions. 

This survey, for HTA producers, aims to explore the learnings from the COVID-19 challenges and if agencies and other HTAers may be able to collaborate beyond their usual practice.

We’re all aware of the international and local needs to improve efficiencies in evidence production, and how this aligns with the work of innovators, regulators and payers. We would therefore welcome your input on how we may be best to approach this.

Please note your responses will be reviewed for internal analysis purposes only and stored on a secure server. Your responses or contact details will not be shared with any third party. We note this survey has not been reviewed and approved by any ethics review entity.

The survey will be open until August 21st, 2020. If you would like to provide comments beyond this time, please email info@htai.org.

Question Title

* 1. Please provide the full name of the HTA agency, MoH department or HTA unit you are representing 

Question Title

* 2. Please enter the country, region, or jurisdiction for which your entity supports decision-making

Question Title

* 3. Please provide your contact email (optional)

Question Title

* 4. Is your agency/department/unit directly involved in any ongoing COVID-19 initiatives related to HTA or evidence-based decision making in your country/region/jurisdiction? Please check all that apply.

Question Title

* 5. When commissioned to complete a COVID-19 related review, how are you determining the assessment 'level' or completeness for a given topic (i.e. lit summary, rapid review, systematic review, full HTA)?

Question Title

* 6. If commissioned to complete a COVID-19 related assessment, what main challenges did/do you face? Please describe. 

Question Title

* 7. Did you need to adapt current standards and procedures in order to respond to the COVID-19 challenges?

Question Title

* 8. If yes, do you think it could have influenced the quality of the deliverable or the potential for re-utilization at a wider level?

Question Title

* 9. Have you been asked to, or have you been able to, within the time constraints, complete any reports which you consider to be ‘full HTA’ (i.e. technology assessments with full analytical scope considering efficacy, safety, cost effectiveness, social, legal, environmental and or other components)?

Question Title

* 10. Did you reuse any report or HTA COVID-19 related output produced by other HTA agencies?

Question Title

* 11. If yes, which components of the report did you reuse?

Question Title

* 12. If not, what are the main reasons?

Question Title

* 13. If a platform existed which provided reports produced by other HTA agencies on topics related to COVID-19, would you reuse available reports, or would your standards and processes restrict against this?

Question Title

* 14. Did the COVID-19 pandemic change in any way how recommendations were formed, or the HTA deliberative processes used within your office? If yes, in what way?

Question Title

* 15. What lessons have you learned from the COVID-19 pandemic related to evidence production that you think would be useful to share with other HTA producers?

Question Title

* 16. Please use this space for any further comments:

T